Condition: Prostate Cancer (Adenocarcinoma) · Blood Loss, Postoperative · Erectile Function · Sponsor: St. Antonius Hospital Gronau
We perform a multicenter randomized controlled prospective study with superiority trial design, in which the polysaccharide ARISTA™ AH hemostat agent is applied to the neurovascular bundle areas after prostate removal, during Robot-assisted radical prostatectomy. We examine if such agent leads to a relevant clinical improvement indicated by higher postoperative hemoglobin levels compared to the control group. As an exploratory co-primary endpoint of interest, we examine erectile function after Robot-assisted radical prostatectomy based on IIEF-5 score between groups 3, 6 and 12 months after Robot-assisted radical prostatectomy
This description comes directly from the study's public registry record.
Sami-Ramzi Leyh-Bannurah, PD. Dr. · +49741051305 · sami-ramzi.leyh-bannurah@uke.de
Always discuss trial participation with your own doctor first.
| Martini Klinik am UKE GmbH | Hamburg, Free and Hanseatic City of Hamburg, Germany | Recruiting |
| St. Antonius-Hospital Gronau GmbH, Klinik für Urologie, Urologische Onkologie und Roboter-assistierte Chirurgie | Gronau, North Rhine-Westphalia, Germany | Recruiting |
| Klinik und Poliklinik für Urologie des Universitätsklinikums Leipzig | Leipzig, Saxony, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06822036